<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04531696</url>
  </required_header>
  <id_info>
    <org_study_id>S64410</org_study_id>
    <nct_id>NCT04531696</nct_id>
  </id_info>
  <brief_title>UZ/KU Leuven Program for Post-mortem Tissue Donation to Enhance Research</brief_title>
  <acronym>UPTIDER</acronym>
  <official_title>UZ/KU Leuven Program for Post-mortem Tissue Donation to Enhance Research</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universiteit Antwerpen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      UPTIDER is a prospective, interventional, non-Investigational Medicinal Product (non-IMP),&#xD;
      non-commercial, single centre post-mortem tissue donation program for metastatic breast&#xD;
      cancer patients or patients with a germline pathogenic variant with a moderate to high&#xD;
      lifetime risk of breast cancer and at least one malignancy at time of death. The overarching&#xD;
      objective of UPTIDER is (i) to unravel metastatic breast cancer evolution, biology,&#xD;
      heterogeneity and treatment resistance and (ii) to assess pathogenicity and tumour biology in&#xD;
      hereditary cancer syndromes with a high lifetime risk of breast cancer; both through&#xD;
      extensive post-mortem multi-level and multi-region sample analysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2020</start_date>
  <completion_date type="Anticipated">September 2035</completion_date>
  <primary_completion_date type="Anticipated">September 2035</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients consenting to participate in the pilot phase</measure>
    <time_frame>Baseline</time_frame>
    <description>Should be equal to or above 50%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median time elapsed between moment of death and start of the autopsy</measure>
    <time_frame>During autopsy</time_frame>
    <description>Should be equal to or less than 12h</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median time elapsed between collection of first and last sample</measure>
    <time_frame>During autopsy</time_frame>
    <description>Should be equal to or less than 8h</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of metastatic organs sampled</measure>
    <time_frame>During autopsy</time_frame>
    <description>Should be equal to or more than 75%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of samples with sufficient quality of DNA extracted</measure>
    <time_frame>During autopsy</time_frame>
    <description>A260/A280 ratio</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of samples with sufficient quality of RNA extracted</measure>
    <time_frame>During autopsy</time_frame>
    <description>RNA integrity number (RIN)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concordance between TILs and clinical response to treatment</measure>
    <time_frame>During autopsy</time_frame>
    <description>Standard histopathological review</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of T cell exhaustion</measure>
    <time_frame>During autopsy</time_frame>
    <description>RNA sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of mutations in each tumor lesion</measure>
    <time_frame>During autopsy</time_frame>
    <description>Whole exome sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of mutations in each tumor lesion</measure>
    <time_frame>During autopsy</time_frame>
    <description>Whole exome sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Tumour Infiltrating Lymphocytes (TILs)</measure>
    <time_frame>During autopsy</time_frame>
    <description>Standard histopathological review</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Hereditary Diseases</condition>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>UPTIDER consists of 8 substudies:&#xD;
Pilot phase&#xD;
Invasive Lobular Carcinoma (ILC) substudy&#xD;
Inflammatory Breast Cancer (IBC) substudy&#xD;
Molecular heterogeneity and treatment response substudy&#xD;
Patient-derived xenograft (PDX) / Patient-derived Organoid (PDO) substudy&#xD;
Metabolomics substudy&#xD;
Liquid biopsy substudy&#xD;
Hereditary cancer syndromes substudy The intervention, consisting of sample collection only, is identical in all substudies, however, the focus of downstream analysis of the samples may be different.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood draw</intervention_name>
    <description>Blood draw at inclusion</description>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Post-mortem tissue collection</intervention_name>
    <description>Sample collection (both liquids, tumour tissue and non-tumour tissue) during post-mortem research autopsy</description>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18 years.&#xD;
&#xD;
          -  Signature of informed consent by the subject.&#xD;
&#xD;
          -  Metastatic breast cancer, or hereditary cancer syndrome with a moderate to high&#xD;
             lifetime risk of breast cancer, for which the patient is treated/followed in UZ&#xD;
             Leuven.&#xD;
&#xD;
        Additional inclusion criteria for the different substudies:&#xD;
&#xD;
          -  Pilot phase: no additional inclusion criteria.&#xD;
&#xD;
          -  ILC substudy: histologically confirmed history of ILC.&#xD;
&#xD;
          -  IBC substudy: history of IBC, fulfilling the following criteria described by Dawood et&#xD;
             al: rapid onset of breast erythema, oedema and/or peau d'orange and/or warm breast&#xD;
             with or without an underlying palpable mass, duration of history of no more than 6&#xD;
             months, erythema occupying at least one-third of the breast and pathological&#xD;
             confirmation of invasive carcinoma.&#xD;
&#xD;
          -  Hereditary cancer syndrome substudy: confirmed presence of a germline mutation known&#xD;
             to be associated with a moderate to high lifetime risk of BC (e.g. known pathogenic&#xD;
             variants in the genes BRCA1/2, CHEK2, TP53, PALB2) and presence of at least one&#xD;
             malignant lesion at time of inclusion (of any origin) .&#xD;
&#xD;
          -  Other substudies: no additional inclusion criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of a transmissible disease that can form a risk to the health of researchers&#xD;
             or others handling the body or patient samples. This includes but is not limited to&#xD;
             the following infectious diseases: human immunodeficiency virus (HIV), active&#xD;
             hepatitis C virus (HCV), encephalitis of unknown cause, Creutzfeldt-Jakob disease,&#xD;
             rabies, active malaria, active tuberculosis, active SARS-CoV-2 infection.&#xD;
&#xD;
          -  Presence of any factors that could logistically or organizationally impede the study&#xD;
             or the performance of sampling within a reasonable post-mortem time frame. This&#xD;
             includes but is not limited to: residence of the subject at a faraway distance from&#xD;
             the UZ Leuven hospital; residence of the subject on territory outside of Belgium;&#xD;
             impossibility to notify the clinician confirming the death and the researchers within&#xD;
             a reasonable time frame in case of death.&#xD;
&#xD;
        Additional exclusion criteria for the different substudies:&#xD;
&#xD;
        - ILC substudy, IBC substudy: diagnosis of a malignancy other than breast cancer in the 5&#xD;
        years prior to inclusion. Exceptions include basal cell carcinoma of the skin or squamous&#xD;
        cell carcinoma of the skin and in situ cervical carcinoma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Giuseppe Floris, MD PhD</last_name>
    <phone>003216336539</phone>
    <email>giuseppe.floris@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine Desmedt, PhD</last_name>
    <phone>003216193306</phone>
    <email>christine.desmedt@kuleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatjana Geukens, MD</last_name>
      <phone>0032475269508</phone>
      <email>tatjana.geukens@kuleuven.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

